Table 1.

Oligonucleotide primers for construction of SIRP-IgG fusion proteins


SIRPα-D1D2 forward  

5′-TAGTAGAAGCTTATGGAGCCCGCCGGCCCGGCC-3′  
SIRPα-D1D2 reverse   5′-TAGTAGGTCGACAACTCGGATGGTCTCAGACAAGTTGG-3′  
SIRPβ1-D1D2 forward   5′-TAGTAGAAGCTTAGACTCACAGGAGTGGCA-3′  
SIRPβ1-D1D2 reverse   5′-TAGTAGGTCGACTGGAACTCGGATGGCCTCAG-3′  
SIRPβ2-D1D2 forward   5′-TAGTAGAAGCTTCTCCAAAATGCCTGTCCCAGCCTCC-3′  
SIRPβ2-D1D2 reverse   5′-TAGTAGGTCGACGGCCTCAGACAAGTTGGCAGTCCC-3′  
Human IgG-Fc forward   5′-TAGTAGGTCGACAAAACTCACACATGCCC-3′  
Human IgG-Fc reverse
 
5′-TAGTAGGGATCCTCATTTACCCGGAGACAGGG-3′
 

SIRPα-D1D2 forward  

5′-TAGTAGAAGCTTATGGAGCCCGCCGGCCCGGCC-3′  
SIRPα-D1D2 reverse   5′-TAGTAGGTCGACAACTCGGATGGTCTCAGACAAGTTGG-3′  
SIRPβ1-D1D2 forward   5′-TAGTAGAAGCTTAGACTCACAGGAGTGGCA-3′  
SIRPβ1-D1D2 reverse   5′-TAGTAGGTCGACTGGAACTCGGATGGCCTCAG-3′  
SIRPβ2-D1D2 forward   5′-TAGTAGAAGCTTCTCCAAAATGCCTGTCCCAGCCTCC-3′  
SIRPβ2-D1D2 reverse   5′-TAGTAGGTCGACGGCCTCAGACAAGTTGGCAGTCCC-3′  
Human IgG-Fc forward   5′-TAGTAGGTCGACAAAACTCACACATGCCC-3′  
Human IgG-Fc reverse
 
5′-TAGTAGGGATCCTCATTTACCCGGAGACAGGG-3′
 

Restriction sites are underlined.

Close Modal

or Create an Account

Close Modal
Close Modal